Teva-Xenon painkiller wins orphan designation from FDA

04/24/2013 | Pharmaceutical Business Review Online

The FDA has granted orphan-drug status to Teva Pharmaceutical and Xenon Pharmaceuticals' XEN402, an experimental drug for pain associated with erythromelalgia. A midstage trial showed that the drug, which inhibits the SCN9A sodium channel, alleviates erythromelalgia-related pain.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA